Novel oral anticoagulants are similar to conventional treatment for venous thromboembolism .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials
BMJ. 2012 Nov 13;345:e7498. doi: 10.1136/bmj.e7498This meta-analysis and systematic review included 9 studies comparing novel oral anticoagulants (with or without initial treatment with heparin) to vitamin K antagonists (always with inital treatment with heparin) in patients with acute venous thromboembolism. From the 9 studies, 16 701 patients were assessed with regards to the efficacy of the drugs and 16 611 were evaluated on safety. Results indicated that there was no difference between any of the anticoagulants compared to the conventional treatment with regards to the rate of recurrent events and mortality. Rivaroxaban was the only novel anticoagulant that resulted in a significant reduction in major bleeding compared to conventional treatment.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
